MBAI.c Expands Capabilities of Flagship AI Platform MedBright AI Investments Inc. (Ticker: MBAI.c or MBAIF for US investors) an investment firm in healthcare technology is advancing its pioneering MedMatrix AI platform through a collaboration with Rejuvenation, a dermatology group renowned for its progressive care, operating across 8 clinics in 3 Provinces.
Despite MBAI's market capitalization being below $20 million, the company has achieved significant milestones, securing agreements with 14 clinics in just two months, including Rejuvenation and a clinic group affiliated with the Yale School of Medicine.
By integrating MedMatrix into its operations, Rejuvenation aims to bolster its capabilities in cosmetic marketing and clinical trial analytics.
The expansion into cosmetic marketing is in line with Rejuvenation's commitment to personalized, advanced care. The newly integrated tool will empower Rejuvenation to pinpoint ideal candidates for cosmetic procedures, offering tailored recommendations to enhance patient experiences and optimize treatment outcomes.
Furthermore, MedMatrix's clinical trial recruitment tools will expedite patient eligibility assessments for clinical trials, enhancing patient access to cutting-edge treatments and streamlining recruitment processes for Rejuvenation's partners, thereby contributing to medical research and innovation.
MBAI's new deal with Rejuvenation not only demonstrates MBAI's ability to forge strong alliances with esteemed medical organizations but also showcases the scalability and swift deployment capabilities of the MedMatrix platform.
Full Press Release: https://www.medbright.ai/blog-posts/medbright-ais-medmatrix-to-expand-its-ai-offerings-for-cosmetic-marketing-clinical-trial-analytics
Posted on behalf of Medbright AI Investments Inc.